Emtricitabine, Rilpivirine, Tenofovir Drug Combination
Semantic Scholar uses AI to extract papers important to this topic.
Background Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co… Expand Objectives
To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral… Expand BackgroundAim of this review is to focus the attention on people living with HIV infection at risk of developing a cardiovascular… Expand BACKGROUND
Completion rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low. We investigated the… Expand Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult… Expand A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non… Expand BACKGROUND
Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV… Expand Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency… Expand The rilpivirine/tenofovir/emtricitabine fixed‐dose combination (RTE FDC) (Complera, Eviplera) is a potent convenient, well… Expand Rilpivirine (RPV) is a new non‐nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non‐inferiority to efavirenz… Expand